Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

Other drugs up for 2027 price decreases include cancer drugs Ibrance, made by Pfizer Inc., Xtandi, made by Pfizer and ...

The U.S. Food and Drug Administration (FDA) gave Amgen (NASDAQ:AMGN) approval to use its KRASG12C inhibitor Lumakras with Vectibix for treating advanced colorectal cancer. Warning! GuruFocus has ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...